Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN, April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.
都柏林，2024年4月29日 /PRNewswire/ — Theravance Biopharma, Inc.（納斯達克股票代碼：TBPH）將在2024年5月13日星期一收盤後公佈其2024年第一季度財務業績，並提供最新業務情況。隨之而來的電話會議和同步網絡直播將在當天美國東部時間下午 5:00（太平洋時間下午 2:00 /美國東部標準時間晚上 10:00）舉行。
Conference Call Information
電話會議信息
To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at , under the Investors section, Events and Presentations.
要通過電話參加直播，請在此處預註冊。有興趣通過互聯網收聽電話會議直播的人可以通過訪問Theravance Biopharma的網站的 “投資者” 欄目下的 “活動和演講” 來收聽電話會議。
A replay of the webcast will be available on Theravance Biopharma's website for 30 days through June 12, 2024.
截至2024年6月12日，網絡直播的重播將在Theravance Biopharma的網站上播放，爲期30天。
About Theravance Biopharma
關於 Theravance Biopharm
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
Theravance Biopharma, Inc. '的重點是交付 有所作爲的藥物 在人們的生活中。爲了實現其目標，Theravance Biopharma利用數十年的專業知識，這促成了經美國食品藥品管理局批准的YUPELRI的開發 （瑞芬那新）吸入溶液適用於慢性阻塞性肺病（COPD）患者的維持治療。Ampreloxetine是其後期在研的每日一次去甲腎上腺素再攝取抑制劑，用於治療多系統萎縮（MSA）患者的症狀性神經源性體位性低血壓（NoH），有可能成爲首款有效治療MSA患者一系列主要症狀的療法。公司致力於創造/推動股東價值。
For more information, please visit .
欲了解更多信息，請訪問。
THERAVANCE BIOPHARMA, THERAVANCE and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
THERAVANCE 生物製藥，THERAVANCE 而且 Cross/Star 徽標是 Theravance Biopharma 集團公司（在美國和其他某些國家）的註冊商標。
YUPELRI is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
YUPELRI 是 Viatris 旗下公司 Mylan Specialty L.P. 的註冊商標。本新聞稿中出現的其他公司的商標、商品名稱或服務商標均爲其各自所有者的財產。
Contact:
[email protected]
650-808-4045
聯繫人：
[電子郵件保護]
650-808-4045
SOURCE Theravance Biopharma, Inc.
來源 Theravance Biopharma, Inc.
譯文內容由第三人軟體翻譯。